Avation Medical Announces Appointment of Chief Marketing Officer to Leadership Team


“I am very excited about the potential of Avation’s easy-to-use portable therapy system,” added Wennen. “The 42 million Americans with OAB and UUI have sent a clear message that they want an effective treatment option that doesn’t require surgery, permanent implants, or drug side effects. Our system combines non-invasive neuromodulation therapy with a digitally enabled behavioral support system, providing patients with a new option that is effective, convenient and safe.”

Mr. Wennen brings to Avation Medical a proven history of successful product launches and sales growth. Most recently, Mr. Wennen served as Vice President of Marketing and Clinical Affairs, as well as Senior Vice President of Commercial Operations, for Tactile Medical (NASDAQ: TCMD), where he helped develop a market for underserved and reimbursement-focused EMR portable devices in Lymphedema, to grow the business to more $200 million in sales and achieve an IPO on the NASDAQ. Earlier in his career, Mr. Wennen held leadership positions at Stryker Orthopedics, Gyrus/ACMI (now Olympus), St. Jude Medical (now Abbott), and Sterilmed (a J&J company). Mr. Wennen holds an MBA in Marketing and International Finance from the University of St. Thomas (St. Paul, MN)and a bachelor’s degree University of Minnesota.

About Avation Medical

Avation Medical is an innovative neuromodulation and digital health company whose mission is to make neuromodulation more accessible to patients in a variety of clinical conditions by eliminating the need for surgery, permanent implants and drug side effects and displacing home treatment. environment. The company’s new platform combines non-invasive neuromodulation therapy with digital health tools to deliver a comprehensive therapy and support system for a range of chronic conditions. The company’s smart wearable therapy objectively confirms target nerve activation, sets a personalized therapy range for each patient, and delivers clinically effective therapy in just 30 minutes. The company’s first product, a wearable neuromodulation and digital behavior assistance system for OAB and UUI, is currently available for experimental use only and is not FDA cleared.

Corporate Contact:
Jackie Gerberry
senior director
[email protected]

SOURCE Medical Aviation


Comments are closed.